Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention

Ruth Nussinov*, Mingzhen Zhang, Chung Jung Tsai, Tsung Jen Liao, David Fushman, Hyunbum Jang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations

Abstract

Autoinhibition is an effective mechanism that guards proteins against spurious activation. Despite its ubiquity, the distinct organizations of the autoinhibited states and their release mechanisms differ. Signaling is most responsive to the cell environment only if a small shift in the equilibrium is required to switch the system from an inactive (occluded) to an active (exposed) state. Ras signaling follows this paradigm. This underscores the challenge in pharmacological intervention to exploit and enhance autoinhibited states. Here, we review autoinhibition and release mechanisms at the membrane focusing on three representative Ras effectors, Raf protein kinase, PI3Kα lipid kinase, and NORE1A (RASSF5) tumor suppressor, and point to the ramifications to drug discovery. We further touch on Ras upstream and downstream signaling, Ras activation, and the Ras superfamily in this light, altogether providing a broad outlook of the principles and complexities of autoinhibition.

Original languageEnglish
Pages (from-to)1263-1282
Number of pages20
JournalBiophysical Reviews
Volume10
Issue number5
DOIs
StatePublished - 1 Oct 2018

Funding

FundersFunder number
National Institutes of HealthHHSN261200800001E
National Institutes of Health
Frederick National Laboratory for Cancer Research

    Keywords

    • Activation
    • Allosteric
    • Drug
    • HRAS
    • Inhibitor
    • K-RAS4A
    • K-RAS4B
    • KRAS
    • NRAS

    Fingerprint

    Dive into the research topics of 'Autoinhibition in Ras effectors Raf, PI3Kα, and RASSF5: a comprehensive review underscoring the challenges in pharmacological intervention'. Together they form a unique fingerprint.

    Cite this